Blog
RSS FeedPosted by Michael Wonder on 05 Jul 2023
TLV is tasked with carrying out health economic assessments of new drugs against cancer
4 July 2023 - The TLV shall carry out health economic assessments of new drugs to be used in clinics, ...
Posted by Michael Wonder on 21 Jun 2023
Imbruvica is included in the high-cost protection with a changed benefit limitation
19 June 2023 - Ibrutinib (Imbruvica)140 mg, 280 mg & 420 mg tablets are now subsidised for the treatment ...
Posted by Michael Wonder on 19 Jun 2023
More measures are needed to curb the development cost of pharmaceuticals
16 June 2023 - There are more and more new drugs, and more people are receiving treatment for their illnesses. At ...
Posted by Michael Wonder on 18 Jun 2023
Health economic assessment of Carvykti in the treatment of multiple myeloma
16 June 2023 - TLV has prepared a health economic assessment for the regions for Carvykti (ciltacabtagene autoleucel). ...
Posted by Michael Wonder on 14 Jun 2023
Health economic assessment of Pluvicto in advanced prostate cancer
12 June 2023 - TLV has produced a health economic assessment for the regions for Pluvicto (Lutetium Lu 177 vipivotide tetraxetan). ...
Posted by Michael Wonder on 13 Jun 2023
The Supreme Administrative Court did not test Mayzent
12 June 2023 - The Supreme Administrative Court decided on 3 May not to grant a review permit for Mayzent. ...
Posted by Michael Wonder on 14 May 2023
The FINOSE collaboration is extended and strengthened by the entry of the Danish Medicines Council
11 May 2023 - On 10 May 2023, the Nordic HTA collaboration FINOSE was extended for another three years and the ...
Posted by Michael Wonder on 12 Apr 2023
TLV has decided on an increase in ceiling prices
12 April 2023 - TLV has decided to increase ceiling prices in certain package size groups. The decision to raise ceiling ...
Posted by Michael Wonder on 04 Apr 2023
TLV reconsiders the subsidy of Lumykras (sotorasib)
4 April 2023 - TLV has started a review of Lumykras (sotorasib). Lumykras (sotorasib) has already been included in the high-cost ...
Posted by Michael Wonder on 02 Apr 2023
Survey on patients' access to medicines for the treatment of rare health conditions
31 March 2023 - The TLV has submitted an interim report to the government for the task of proposing how ...
Posted by Michael Wonder on 28 Mar 2023
Clarification on the subsidy limitation for drugs for diabetes
28 March 2023 - The TLV has clarified the subsidy limitation for all GLP-1 receptor agonists. ...
Posted by Michael Wonder on 27 Mar 2023
Final reconciliation of savings from side agreements for the full year 2022
28 March 2023 - The TLV has presented the Government with the final reconciliation of the outcome of savings from ...
Posted by Michael Wonder on 25 Mar 2023
TLV is preparing for an increase in ceiling prices
17 March 2023 - In order to ensure continued good access to medicines for patients, TLV started in the autumn of ...
Posted by Michael Wonder on 16 Feb 2023
Health economic assessment of Kimmtrak in disseminated ocular melanoma
16 February 2023 - The assessment applies to Kimmtrak as the sole treatment for adult patients with melanoma in the ...
Posted by Michael Wonder on 06 Feb 2023
TLV proposes a new process for health economic assessments that are made in a short time and under special circumstances
1 February 2023 - In a report to the government, the Dental and Pharmaceutical Benefits Agency, TLV, presents experiences and lessons ...